Depression Screening and Patient Outcomes in Cancer: A Systematic Review
Open Access
- 14 November 2011
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27181
Abstract
Several practice guidelines recommend screening for depression in cancer care, but no systematic reviews have examined whether there is evidence that depression screening benefits cancer patients. The objective was to evaluate the potential benefits of depression screening in cancer patients by assessing the (1) accuracy of depression screening tools; (2) effectiveness of depression treatment; and (3) effect of depression screening, either alone or in the context of comprehensive depression care, on depression outcomes. Data sources were CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO and SCOPUS databases through January 24, 2011; manual journal searches; reference lists; citation tracking; trial registry reviews. Articles on cancer patients were included if they (1) compared a depression screening instrument to a valid criterion for major depressive disorder (MDD); (2) compared depression treatment with placebo or usual care in a randomized controlled trial (RCT); (3) assessed the effect of screening on depression outcomes in a RCT. There were 19 studies of screening accuracy, 1 MDD treatment RCT, but no RCTs that investigated effects of screening on depression outcomes. Screening accuracy studies generally had small sample sizes (median = 17 depression cases) and used exploratory methods to set sample-specific cutoff scores that varied substantially across studies. A nurse-delivered intervention for MDD reduced depressive symptoms moderately (effect size = 0.37). The one treatment study reviewed reported modest improvement in depressive symptoms, but no evidence was found on whether or not depression screening in cancer patients, either alone or in the context of optimal depression care, improves depression outcomes compared to usual care. Depression screening in cancer should be evaluated in a RCT in which all patients identified as depressed, either through screening or via physician recognition and referral in a control group, have access to comprehensive depression care.Keywords
This publication has 52 references indexed in Scilit:
- Rethinking recommendations for screening for depression in primary careCanadian Medical Association Journal, 2011
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenActa Oncologica, 2010
- Evaluation of screening instruments for depression and anxiety in breast cancer survivorsBreast Cancer Research and Treatment, 2009
- Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With CancerJournal of Clinical Oncology, 2008
- Screening and case-finding instruments for depression: a meta-analysisCanadian Medical Association Journal, 2008
- Screening for Depression in Terminally Ill Cancer Patients in JapanJournal of Pain and Symptom Management, 2006
- Rasch analysis of the dimensional structure of the Hospital Anxiety and Depression ScalePsycho-Oncology, 2005
- Providing psychosocial support for breast cancer patients based on screening for distress within a consultation‐liaison servicePsycho-Oncology, 2004
- An Attempt to Employ the Zung Self-Rating Depression Scale as a “Lab Test” to Trigger Follow-Up in Ambulatory Oncology ClinicsJournal of Pain and Symptom Management, 2001
- Meta-Analysis: Recent Developments in Quantitative Methods for Literature ReviewsAnnual Review of Psychology, 2001